Clinical Trial Update: A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. [Phase 1]

View source ↗

Summary

Sanofi completed a Phase 1 clinical trial evaluating the safety and immunogenicity of vaccines targeting influenza, respiratory syncytial virus, human metapneum…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Metapneumovirus Infection
• Parainfluenza Virus Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• Human metapneumovirus vaccine (Sanofi) (Human metapneumovirus vaccine)
• Influenza vaccine (Sanofi) (Influenza vaccine)
• Parainfluenza vaccine (Sanofi) (Parainfluenza vaccine)
• RSV vaccine (Sanofi) (Respiratory syncytial virus vaccine)

Snippet

Sponsor: Sanofi | Conditions: Healthy Volunteers, Influenza Vaccination | Phase 1 | Status: COMPLETED